在上皮卵巢癌中BAF312 (西波尼莫德) 的抗癌作用
Heeeun Ha1, Ji-Yoon Ryu2, Suin Yoon1
1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Anticancer research
|September 30, 2024
概括
BAF312是一种基-1-受体调节剂,通过抑制ERK和AKT通路,对上皮卵巢癌 (EOC) 产生显著的抗癌作用. 这表明BAF312是EOC治疗的潜在治疗剂.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 卵巢上皮癌 (EOC) 是女性癌症相关死亡的主要原因.
- BAF312 (siponimod) 是一种S1P受体调节器,具有已知的免疫调节和临床前抗瘤作用.
- BAF312对EOC的潜力在很大程度上仍未被探索.
研究的目的:
- 研究BAF312对上皮卵巢癌 (EOC) 的抗癌特性.
- 评估BAF312在体外和体外EOC模型中的疗效.
- 阐明BAF312抗EOC作用背后的分子机制.
主要方法:
- 在体外测试中评估了BAF312治疗后的EOC细胞增殖,细胞亡和迁移.
- 西方斑点分析研究了斯芬戈-1-酸盐受体1 (S1PR1),AKT和ERK的表达.
- 在体内有效性使用BAF312装载纳米颗粒 (PLGA-NP-BAF312) 在正位点小鼠模型中进行了评估.
主要成果:
- BAF312显著降低了EOC细胞的增殖和迁移,同时诱导了细胞亡.
- 在大多数EOC细胞系中观察到S1PR1的过度表达.
- 在体内,PLGA-NP-BAF312治疗有效降低了瘤体重,与减少ERK和AKT酸化有关.
结论:
- BAF312在上皮卵巢癌中表现出显著的抗癌作用.
- 抑制ERK和AKT通路调解BAF312的抗EOC活性.
- BAF312证明了作为EOC治疗的新型治疗剂的潜力.
更多相关视频
05:42Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
2.5K
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
8.4K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K